ライフサイエンスコーパス: cobra

1 hod of combined bisulfite restriction assay (COBRA).

2 by combined bisulfite restriction analysis (COBRA).

3 or combined bisulfite restriction analysis (COBRA).

4 tionally optimized broadly reactive antigen (COBRA).

5 ay [combined bisulfite restriction analysis (COBRA)].

6 with some of them being easily detectible by COBRA.

7 us and can be quantitatively monitored by SB-COBRA.

8 ends beyond the sequence design space of the COBRA.

9 stent with its role at retrieval proposed by CoBRA.

10 howed that FastMM is 2~400 times faster than COBRA 3.0 in performing flux balance analysis and knocko

11 Here, we rewrote the underlying code of COBRA 3.0 using C/C++, and developed a toolbox, termed F

12 This interface was fully compatible with COBRA 3.0, enabling users to easily perform complex appl

13 Although the state-of-art modeling toolbox, COBRA 3.0, is powerful, it requires substantial computin

14 MCMC sampling, FastMM is 8 times faster than COBRA 3.0.

15 provement to the existing functionalities in COBRA 3.0.

16 mal genome assembly of Naja naja, the Indian cobra, a highly venomous, medically important snake.

17 Here, we describe Bio-COBRA, a modified protocol for Combined Bisulfite Restri

18 e "cortical binding of relational activity" (CoBRA) account (Shimamura, 2011), which suggests that th

19 COBRA accurately joined the assembled sequences and achi

20 erformed a screen for genetic suppressors of cobra, an Arabidopsis mutant with defects in cellulose f

21 COBRA analysis in HCT-116 colon cancer cells revealed a

22 peptides (9), fasciclin-like proteins (20), COBRA and 10 homologs, and novel potential signaling pep

23 alone web-based tool and as plug-ins for the COBRA and COBRApy toolboxes.

24 We next studied 53 patients by COBRA and demonstrated that 72% of patient samples with

25 primers for bisulfite-PCRs (MSP, sequencing, COBRA and multiplex-MSP), allowing the determination of

26 tors of cellulose synthesis, suggesting that COBRA and the cellulose synthase complex reside in close

27 The cobra and viper venoms-induced sterile inflammatory mole

28 COBRA and wild-type E antigens were expressed on the sur

29 e a novel Computational Brewing Application (COBRA) and apply it to modeling oligomerization chemistr

30 Combined Bisulfite Restriction Analysis (COBRA) and bisulfite sequencing analysis revealed that t

31 and combined bisulfite restriction analysis (COBRA), and quantitative SB-COBRA was performed to study

32 Using the COBRA methodology, H2 HA COBRA antigens were designed using sequences from H2N2 v

33 ode integration also enables an expansion in COBRA application scope via high-precision, high-perform

34 Using the COBRA approach, a set of vaccines against influenza viru

35 We recently identified COB (COBRA) as a key regulator of the orientation of cell exp

36 The Bio-COBRA assay can be performed on 12 samples in less than

37 This is the first report describing a COBRA-based HA vaccine strategy that elicits a broadly r

38 This is the first report describing a COBRA-based HA vaccine strategy that elicits a universal

39 Overall, H3 COBRA-based HA vaccines were able to neutralize both his

40 rt the development and characterization of a COBRA-based vaccine for both seasonal and pandemic H1N1

41 Competition assays suggests that COBRA binds individual beta1-4-linked glucan chains with

42 In contrast to properdin, both gCs bound to cobra C3; this finding suggests that gC-1 and properdin

43 ntology and Open Biology Ontologies formats, COBrA can import and export ontologies in the Semantic W

44 Bites by elapid snakes (e.g. cobras) can result in life-threatening paralysis caused

45 In addition, several COBRA candidates were designed based on sequences of H1N

46 Nine HA COBRA candidates were developed, and these vaccines were

47 Cobra cardiotoxins (CTX) are a family of three-fingered

48 onsistent with their ability to suppress the cobra cellulose deficiency.

49 Cynomolgus macaques vaccinated with COBRA clade 2 HA H5N1 virus-like particles (VLPs) had he

50 The COBRA clade 2 HA H5N1 VLP elicits broad humoral immunity

51 Mutations in the COBRA (COB) gene of Arabidopsis, known to affect the ori

52 abidopsis (Arabidopsis thaliana) root is the COBRA (COB) gene that belongs to a multigene family.

53 COBRA (COB) has been identified previously as a potentia

54 ts with severe asthma as comparative groups (COBRA cohort [Cohorte Obstruction Bronchique et Asthme;

55 ng from the Comorbidity in Relation to AIDS (COBRA) cohort.

56 In this report, we describe Bio-COBRA (combined bisulfite restriction analysis coupled w

57 Antibodies elicited by COBRA DENV E immunogens neutralized all 12 strains of DE

58 COBRA DENV SVPs elicited a broader breadth of antibodies

59 mples are presented where the performance of COBRA, DyMMM and DFBAlab are compared.

60 COBRA estimates a reduced set of parameters expressing t

61 et the available evidence as suggesting that COBRA facilitates cellulose crystallization from the eme

62 Onstraint Based Reconstruction and Analysis (COBRA) flux prediction algorithms fail.

63 roadly reactive hemagglutinin (HA) antigens (COBRA) for H1N1 isolates.

64 ionally optimized broadly reactive antigens (COBRA) for hemagglutinin (HA).

65 onstraint-based reconstruction and analysis (COBRA) framework has been widely used to study steady-st

66 Mutations in the Arabidopsis COBRA gene lead to defects in cellulose synthesis but th

67 We compare the python and king cobra genomes along with genomic samples from other snak

68 Bivalent mixtures of COBRA H1 and H3 rHA, Y2 + J4, and Y2 + NG2 outperformed

69 Multiple COBRA H2 HA vaccines protected mice from all three viral

70 COBRA H2 HA vaccines were developed and evaluated in mic

71 HA from a wild-type H3 influenza virus or a COBRA H3 HA antigen (T6, T7, T10, or T11).

72 In this study, the effectiveness of H2 COBRA HA antigens (Z1, Z3, Z5, and Z7) was evaluated in

73 ntibodies induced by wild-type H1N1 viruses, COBRA HA antigens elicited sera with the broadest HAI re

74 seasonal-like and pandemic-like wild-type or COBRA HA antigens were exchanged with homologous regions

75 modified HA antigens (designated V1 to V12), COBRA HA antigens, or wild-type HA antigens.

76 fected with influenza viruses expressing the COBRA HA antigens.

77 ferrets with COBRA HA based viruses or using COBRA HA based vaccines to boost preexisting antibodies

78 Overall, priming naive ferrets with COBRA HA based viruses or using COBRA HA based vaccines

79 The top leading COBRA HA candidates were tested against cocirculating va

80 This COBRA HA elicited a broad antibody response against H5N1

81 Four of the 9 H1N1 COBRA HA proteins (X1, X3, X6, and P1) had the broadest

82 irus-like particle (VLP) vaccines expressing COBRA HA proteins elicited antibodies with hemagglutinat

83 ere exchanged with homologous regions in the COBRA HA proteins to determine which regions and residue

84 Nine prototype H1N1 COBRA HA proteins were developed and tested in mice usin

85 nt and characterization of 17 prototype H3N2 COBRA HA proteins were screened in mice and ferrets for

86 memory B cells will likely be recalled upon COBRA HA vaccination.

87 The T-11 COBRA HA vaccine elicited antibodies with HAI and neutra

88 The most effective COBRA HA vaccine regimens elicited antibodies with broad

89 The COBRA HA vaccines elicited neutralizing antibodies to th

90 irst study to show the effectiveness of H3N3 COBRA HA vaccines in a host with preexisting immunity to

91 Additionally, M7-NH(2) adjuvanted COBRA HA vaccines induced Th2 skewed immune responses wi

92 Two candidate COBRA HA vaccines, P1 and X6, elicited antibodies with d

93 To mimic the human condition, COBRA HA virus-like particle vaccines were tested in fer

94 rus and vaccinated with a single dose of the COBRA HA VLP vaccines elicited antibodies with HAI activ

95 eadth of HAI activity after vaccination with COBRA HA VLP vaccines than COBRA preimmune ferrets vacci

96 nism(s) of expanded Ab breadth elicited by a COBRA HA-based immunogen and advances efforts toward des

97 iming naive ferrets with broadly reactive H1 COBRA HA-based vaccines boosted preexisting antibodies i

98 ) Ab-secreting cells elicited by a candidate COBRA hemagglutinin (HA) (termed P1) were compared with

99 These H1 COBRA hemagglutinin (HA) antigens induced antibodies wit

100 ing combined bisulfite restriction analysis (COBRA), hypermethylation of this fragment was detected i

101 e imposition of loop-law constraints with ll-COBRA improves the consistency of simulation results wit

102 COBRA improves viral genome assembly contiguity and comp

103 COBrA is a Java-based ontology editor for bio-ontologies

104 In particular, the Z1 COBRA is a promising candidate for future work toward a

105 COBRA is available under the GLP3 open source license in

106 COBRA is computationally efficient, leveraging the inher

107 Although the king cobra is limbless, we recovered coding sequences for all

108 COBRA is not limited to atmospheric aerosol chemistry; i

109 s in cellulose synthesis but the function of COBRA is unknown.

110 onstraint-Based Reconstruction and Analysis (COBRA) is currently the only methodology that permits in

111 on influenza vaccines, such as HA head-based COBRA, is to stimulate broadly protective neutralizing a

112 of the glycosylphosphatidylinositol-anchored COBRA-LIKE gene family in Arabidopsis (Arabidopsis thali

113 andidate gene approach and found to encode a COBRA-like protein similar to rice (Oryza sativa) BC1 an

114 n patterns for transcripts of genes encoding COBRA-like proteins and other cell wall metabolism-relat

115 he course of seed development, we identified COBRA-LIKE2 (COBL2), a member of the glycosylphosphatidy

116 ) BC1 and Arabidopsis (Arabidopsis thaliana) COBRA-LIKE4.

117 integer programming approach called loopless COBRA (ll-COBRA), which can be used to eliminate all ste

118 Here we present evidence that COBRA localizes to discrete particles in the plasma memb

119 The sensitivity and reproducibility of Bio-COBRA make it a valuable tool for the analysis of DNA me

120 Using the COBRA methodology, H2 HA COBRA antigens were designed us

121 tionally optimized broadly reactive antigen (COBRA) methodology against H1N1, H3N2, and H5N1 viruses.

122 One shortcoming of current COBRA methods is the possible violation of the loop law

123 ysis (McCOBRA), which adapt standard MSP and COBRA methods to a melting curve analysis based platform

124 d provides an additional constraint for many COBRA methods, enabling the acquisition of more realisti

125 A Toolbox, a MATLAB package for implementing COBRA methods, was presented earlier.

126 lowers the barrier of entry to use powerful COBRA methods.

127 lbox v.3.0 provides an unparalleled depth of COBRA methods.

128 sive desktop software suite of interoperable COBRA methods.

129 to improve flux predictions on three common COBRA methods: flux balance analysis, flux variability a

130 onstraint-based reconstruction and analysis (COBRA) methods at the genome scale have been under devel

131 onstraint-based reconstruction and analysis (COBRA) methods to simulate, analyze and predict a variet

132 ic resonance studies of the cell wall of the cobra mutant also indicated that, in addition to decreas

133 ynthesis appeared to proceed normally in the cobra mutant.

134 When separated from the cobra mutation, mutations in MED16 caused resistance to

135 by combined bisulfite restriction analysis (COBRA); mutation of K-ras, p53, p16, and p14 genes by se

136 ter cobras Naja annulata, and eastern forest cobras N. subfulva).

137 lylepis, Jameson's mambas D. jamesoni, water cobras Naja annulata, and eastern forest cobras N. subfu

138 holipase A2 (PLA2) from the venom of Chinese cobra (Naja naja atra) has high activity on zwitterionic

139 diameter) are exposed to PLA2 isolated from cobra (Naja naja naja) venom at varying enzyme concentra

140 Diabetics With Peripheral Vascular Disease [COBRA]; NCT00827853).

141 ted the genome of a venomous snake, the king cobra (Ophiophagus hannah), and compared it, together wi

142 Although venoms from king cobra (Ophiophagus hannah; OH) and green pit viper (Trim

143 we created a rAAV viral vector expressing a COBRA-optimized influenza hemagglutinin antigen with mod

144 enerated following immunization of mice with COBRA P1 and the corresponding purified mAbs were charac

145 (mon1) that suppressed the growth defects of cobra, partially restored cellulose levels, and restored

146 opically expressed, partially suppressed the cobra phenotype.

147 These COBRA preimmune ferrets had superior breadth of HAI acti

148 vaccination with COBRA HA VLP vaccines than COBRA preimmune ferrets vaccinated with VLP vaccines exp

149 n be flexibly combined to implement tailored COBRA protocols for any biochemical network.

150 Bio-COBRA provides a platform for the rapid and quantitative

151 onstraint-based reconstruction and analysis (COBRA) provides a molecular mechanistic framework for in

152 nmethylated from methylated Cytosines (i.e., COBRA, pyrosequencing).

153 d into 5 different families: Supine, Convex, Cobra, Stretch, and Concave motifs.

154 Preimmune animals vaccinated with H3 COBRA T10 HA antigen elicited sera with higher hemagglut

155 very diverse, with ~300 terrestrial species (cobras, taipans, etc.) and ~60 fully marine sea snakes,

156 putationally optimized broadly reactive Ags (COBRA) targeting H1 elicit a broad cross-reactive and cr

157 We have used COBRA technology to develop an HA head-based strategy th

158 COBRA technology was effectively used to design HA immun

159 Building upon the COBRA technology, nine next-generation H3N2 influenza he

160 of Hemachatus haemachatus (African Ringhals cobra) that specifically inhibits factor X (FX) activati

161 for Combined Bisulfite Restriction Analysis (COBRA), that incorporates an electrophoresis step in mic

162 COBRA thus combines the powerful features of ease of use

163 port here on a quantitative technique called COBRA to determine DNA methylation levels at specific ge

164 e apply a Computational Brewing Application (COBRA) to simulate the oxidation of squalene in the pres

165 Version 2.0 of the COBRA Toolbox expands the scope of computations by inclu

166 The COBRA Toolbox is a comprehensive desktop software suite

167 As with the first version, the COBRA Toolbox reads and writes systems biology markup la

168 This protocol is an update to the COBRA Toolbox v.1.0 and v.2.0.

169 The COBRA Toolbox v.3.0 provides an unparalleled depth of CO

170 The COBRA Toolbox, a MATLAB package for implementing COBRA m

171 t for compatibility with old versions of the COBRA toolbox.

172 of a combination treatment in early RA (the COBRA trial), and 1 placebo-controlled trial of a new de

173 COBRA uses two lists as input: a list of chemical struct

174 However, while the T11 COBRA vaccine did not elicit HAI activity, the elicited

175 Therefore, the COBRA vaccines have the ability to elicit protective ant

176 Three of the H3N2 COBRA vaccines recognized all of the cocirculating strai

177 DBA/2J mice vaccinated with COBRA vaccines showed increase survival for all three vi

178 Cobra venom (Naja kaouthia) contains a toxin called alph

179 Phospholipase A2 from cobra venom (Naja naja atra) hydrolyzes carbonothioate p

180 xchange mass spectrometric evaluation of the cobra venom (Naja naja naja) group IA phospholipase A 2

181 Beta-cardiotoxin (B-CTX) from the king cobra venom (Ophiophagus hannah) was previously proposed

182 Rats given cobra venom factor (CoF) followed by a NTS shown to be c

183 epleting complement in chinchillas by use of cobra venom factor (CoVF) rendered two otherwise avirule

184 Cobra venom factor (CoVF) treatment, which depletes C3 a

185 562 alone (HAR model) or in combination with cobra venom factor (CVF) (DXR model).

186 r first hamster hearts had been surviving in cobra venom factor (CVF) + CyA-treated rats for 10 days,

187 administered the complement-depleting agent cobra venom factor (CVF) 24 hr before HI lesioning and e

188 nografts, the inhibition of complement using cobra venom factor (CVF) accelerates pulmonary xenograft

189 the graft aorta in combination with systemic cobra venom factor (CVF) administration to deplete compl

190 prevented by brief complement inhibition by cobra venom factor (CVF) and sustained T-cell immunosupp

191 Surprisingly, injection of cobra venom factor (CVF) caused a profound and reproduci

192 Cobra venom factor (CVF) depletes complement and may the

193 anted heterotopically into rats treated with cobra venom factor (CVF) develop disease over 72 hours.

194 me of primary immunization by treatment with cobra venom factor (CVF) diminished serum anti-PPS14 con

195 dy sought to (i) investigate the efficacy of cobra venom factor (CVF) in preventing hyperacute reject

196 Cobra venom factor (CVF) induces lung injury through oxi

197 activation of complement by i.v. infusion of cobra venom factor (CVF) is known to be P-selectin depen

198 in vivo, because complement depletion using cobra venom factor (CVF) markedly reduced the efficacy o

199 y after systemic activation of complement by cobra venom factor (CVF) or after intrapulmonary deposit

200 or inhibited by intraperitoneal injection of cobra venom factor (CVF) or complement receptor-related

201 enografts was achieved using either CsA plus cobra venom factor (CVF) or CsA plus rapamycin.

202 depletion by treatment of athymic rats with cobra venom factor (CVF) partially reverses this effect.

203 Transient complement inhibition with cobra venom factor (CVF) plus daily and continuing cyclo

204 Intraperitoneal injection of cobra venom factor (CVF) reduced C3 levels in the cornea

205 on of complement C3 or its inactivation with Cobra Venom Factor (CVF) result in impaired muscle regen

206 ell activation when it was preincubated with cobra venom factor (CVF) to deplete C3.

207 ing pulmonary xenograft dysfunction by using cobra venom factor (CVF) to deplete recipient complement

208 Administration of cobra venom factor (CVF), 1 day before and at the time o

209 xplored by intraperitoneal injection of 35 U cobra venom factor (CVF), 24 hours before antibody injec

210 s B or D but did bind to immobilized C3b and cobra venom factor (CVF), a C3b analogue.

211 A/2 as islet allograft recipients as well as cobra venom factor (CVF), a complement blocker, treatmen

212 l plasma, with or without heat inactivation, cobra venom factor (CVF), or lipopolysaccharide plus int

213 groups: no therapy, daily administration of cobra venom factor (CVF), or splenectomy plus daily CVF.

214 (MMF), anti-CD40L monoclonal antibody (mAb), cobra venom factor (CVF), pig hematopoietic growth facto

215 as generated in vivo by infusion of purified cobra venom factor (CVF), thymocyte apoptosis was signif

216 ction process was further investigated using cobra venom factor (CVF), which systemically depleted th

217 ties, but had normal susceptibilities to the cobra venom factor (CVF)-dependent convertase.

218 Median graft survival was 62 hr in cobra venom factor (CVF)-treated controls versus 108 hr

219 rats treated with cyclosporine (CsA) and/or cobra venom factor (CVF).

220 respond to intravenous injection of purified cobra venom factor (CVF).

221 vation and depletion of complement (C) using cobra venom factor (CVF).

222 (GV) with the induction of lung injury using cobra venom factor (CVF); b) PLV-CVF group, animals rece

223 ion was significantly (p < 0.001) delayed by cobra venom factor (CVF; 11 +/- 8 h in four of five case

224 1 microg/mouse), we depleted complement with cobra venom factor (CVF; 7 U/mouse, intravenously [i.v.]

225 A convertase assembled with cobra venom factor and Bb was decayed by DAF, albeit far

226 health and disease; for instance, the use of cobra venom factor and depletion of C3 provided the init

227 was inhibited by complement depletion using cobra venom factor and did not develop in C3(-/-) mice.

228 llowing systemic activation of complement by cobra venom factor and in the L-selectin-, P-selectin-,

229 eukostasis in mice systemically infused with cobra venom factor and intrapulmonary transendothelial m

230 term after transient complement depletion by cobra venom factor and T cell immunosuppression by cyclo

231 ic activation by the alternative pathway and cobra venom factor C3 convertases; and 4) for susceptibi

232 Cobra venom factor completely inhibited complement activ

233 This transient protection was abrogated by cobra venom factor depletion of complement from FcgammaR

234 C3(-/-) mice, and control mice injected with cobra venom factor developed pronounced corneal opacific

235 Treatment with cobra venom factor did not affect survival, confirming t

236 Depletion of circulating complement with cobra venom factor eliminated, as expected, injury recor

237 after elastase perfusion, mice treated with cobra venom factor exhibited a mean aortic diameter of 9

238 t C3 in the periphery through treatment with cobra venom factor had a seizure rate comparable to that

239 Injecting cobra venom factor into wild-type mice activated the AP

240 e LPS injection, activation of complement by cobra venom factor led to significant elevation of serum

241 In the cobra venom factor model, sCR1sLex and sCR1[desLHR-A]sLe

242 In monkeys that received neither cobra venom factor nor dextran sulfate (group 1), there

243 The effect of complement depletion with cobra venom factor on porcine bone marrow cell (BMC) eng

244 When compared with the cobra venom factor only group (GV-CVF 47 +/- 2 neutrophi

245 ated injury, either by the administration of cobra venom factor or soluble complement receptor I to t

246 diac transplants to survive long term (i.e., cobra venom factor plus cyclosporin A), inhibition of HO

247 nt depletion in CD55(-/-)CD59(-/-) mice with cobra venom factor prevented these effects.

248 Decomplementation by cobra venom factor resulted in impaired entry of hepatoc

249 Injection of cobra venom factor resulted in prolongation of cardiac x

250 pig hearts transplanted into rats treated by cobra venom factor to avoid the hyperacute rejection.

251 Treatment of mice with cobra venom factor to deplete complement had insignifica

252 block C4 and C3 split product binding or by cobra venom factor to trigger C3 consumption.

253 required for the protective effect of CRP as cobra venom factor treatment eliminated the effect of CR

254 ontributed to serum-induced dry eye disease, cobra venom factor was used to deplete complement activi

255 els, C3(-/-) mice and mice depleted of C3 by cobra venom factor were more susceptible to C. neoforman

256 type mice cotreated with the TLR ligands and cobra venom factor, a potent complement activator.

257 y experiments using serum with added EDTA or cobra venom factor, a protein that depletes C3.

258 DAF did not bind cobra venom factor, implying that Bb decay is accelerate

259 i-T-cell and natural killer cell antibodies, cobra venom factor, medronate-liposomes, and 4 Gy of who

260 swine kidney, maintenance therapy comprised cobra venom factor, mycophenolate mofetil, and an anti-C

261 T-cell depletion, complement depletion with cobra venom factor, mycophenolate mofetil, anti-CD154 mo

262 scued in E8.5 Cmas-/- mice upon injection of cobra venom factor, resulting in exhaustion of the mater

263 hymocyte globulin, complement depletion with cobra venom factor, short courses of anti-CD154 mAb ther

264 epletion with ATG, complement depletion with cobra venom factor, short courses of cyclosporine, mycop

265 howed that pretreatment of C57BL/6 mice with cobra venom factor, which depleted serum of complement a

266 globulin, an anti-CD20 mAb (Rituximab), and cobra venom factor, with maintenance therapy based on bl

267 ubstituted with the corresponding segment of cobra venom factor, Xenopus, or trout C3 (chimeric C3s)

268 determined the C5-cleaving properties of the cobra venom factor-dependent C5 convertase (CVF, Bb) mad

269 In contrast, zymosan- and cobra venom factor-induced AP complement activation, and

270 In the present study, we used cobra venom factor-induced decomplementation to investig

271 gammaR(-/-) mice, but not in C3(-/-) mice or cobra venom factor-treated mice.

272 rmal Lewis rats (complement-sufficient) with cobra venom factor-treated rats (complement-depleted).

273 rogenitor cells in marrow, were increased in cobra venom factor-treated recipients compared with simu

274 shock due to acute complement activation by cobra venom factor.

275 Sterne strain upon complement depletion with cobra venom factor.

276 en complement was depleted by treatment with cobra venom factor.

277 Lewis rats, using intravenously administered cobra venom factor.

278 complement components via pretreatment with cobra venom factor.

279 t participated in AP activation initiated by cobra venom factor.

280 pressure (PEEP) before the administration of cobra venom factor; d) CVF-PLV group, animals received p

281 ls received partial liquid ventilation after cobra venom factor; e) CVF-PEEP group, animals received

282 CVF-PEEP group, animals received PEEP after cobra venom factor; f) PLV only group, animals received

283 to the GP Ib thrombin-binding site or by the cobra venom metalloproteinase, mocarhagin, that hydrolyz

284 n Ib-IX-V complex, we utilized mocarhagin, a cobra venom metalloproteinase, to generate a fragment (H

285 Cardiotoxins (CTXs) from cobra venom show cytotoxicity toward several cell types.

286 ants of the group IA phospholipase A(2) from cobra venom were constructed and expressed in the methyl

287 act with CTX A3, a major component of Taiwan cobra venom, by use of affinity chromatography, circular

288 In Naja kaouthia cobra venom, we have earlier discovered a covalent dimer

289 Naja sputatrix (Malayan spitting cobra) venom contains 15% secretory PLA2 of its dry weig

290 hallenge were vaccines that contained the P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

291 In addition, the COBRA VLP vaccine is more effective than a homologous va

292 ned the P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

293 However, COBRA VLP-vaccinated nonhuman primates had reduced lung

294 Using isothermal calorimetry, COBRA was found to bind individual beta1-4-linked glucan

295 iction analysis (COBRA), and quantitative SB-COBRA was performed to study methylation of the TWIST2 p

296 ionally optimized broadly reactive antigens (COBRA) was used to design novel hemagglutinin (HA) vacci

297 y abundant CTX homologues from the Taiwanese cobra, we showed that slight variations on the spatial d

298 ogramming approach called loopless COBRA (ll-COBRA), which can be used to eliminate all steady-state

299 tionally optimized broadly reactive antigen (COBRA), which uses worldwide sequencing and surveillance

300 he combination of a well-established method, COBRA, which interrogates DNA methylation via the restri